Shanghai GOBROAD Cancer Hospital, affiliated with China Pharmaceutical University, has published a consolidated summary of the clinical research projects it is currently running. The hospital is a research-oriented oncology institution that conducts its clinical studies under the research platform of the university, with the aim of standardising the way new diagnostic and treatment approaches are evaluated. The summary is released so that patients and their families can see, in one place, which clinical research resources are within reach of them.
Rather than presenting the projects study by study, the October 2026 summary is organised as two parallel indexes. One indexes every open project by tumor type, the other by molecular target. Every entry in both indexes is marked as actively recruiting, and each carries a request route for patients who want to know more about that particular line of research.
Eleven Tumor Types Currently Recruiting
The first index groups the open projects by the tumor type they address. Nine named solid tumors and one rare thoracic entity are listed, together with an "other tumors" track that collects studies which do not sit inside a single disease group, giving eleven tracks in total.
- Stomach Cancer
- Colorectal Cancer
- Esophageal Squamous Cell Carcinoma
- Pancreatic Cancer
- Biliary Tract Cancer
- Lung Cancer
- Liver Cancer
- Breast Cancer
- Kidney Cancer
- NUT Midline Carcinoma
- Other Tumors
Sixteen Molecular Targets Currently Recruiting
The second index cuts across tumor types and groups the same project pool by the molecular alteration a study is designed to act on. It runs from well-established targets such as EGFR, HER-2 and BRAF through to newer entries like CLDN6, CLDN8.2 and KRAS G12D, and it includes one track defined by a signalling pathway rather than a single gene.
- PTEN
- BRAF
- FGFR2b
- MTAP
- CLDN8.2
- HER-2
- EGFR
- BRCA1/2
- HRR-Related Genes
- CCNE1 Amplification
- FGFR2
- KRAS G12D
- NUT
- CLDN6
- FGF19
- Abnormal Activation of the MAPK Signaling Pathway (RAS/RAF/MEK/ERK)
What a Listing Does and Does Not Mean
A track appearing in the summary means that the hospital has at least one open study in that area. It does not mean that any particular patient is eligible. Whether a patient fits a given study can only be settled after a complete set of examinations has been reviewed and the study investigator has made an assessment, and the hospital states this explicitly alongside the list.
For patients and referring physicians outside China, the practical first step is a review of the pathology report, the molecular profiling results and the treatment history against the two indexes above. Molecular results matter as much as the diagnosis here, because sixteen of the twenty-seven entries across the two indexes are organised by alteration rather than by tumor type, so a patient whose cancer has already been sequenced may match a target track even where the disease group itself is not listed.
Requesting Project Details
Patients who want the full protocol-level details of a study, including its phase, the investigational agent, the eligibility criteria and the commitment it involves, can request them through the MedTourChina central line listed below. The hospital undertakes to handle personal information in strict confidence and in line with the applicable requirements, and it welcomes enquiries and participation from patients both inside and outside China.
Enquiries are reviewed in English, and the project brief for a given tumor type or target can be provided before any commitment to travel is made.
About the Hospital
Shanghai GOBROAD Cancer Hospital is located at 170 Taibei East Road in the Pudong New Area of Shanghai. It is a tertiary medical insurance designated institution with a total floor area of around 70,000 square metres. Four hundred beds are open in the first phase, a second phase is under construction and is expected to come into use in 2027, and the two phases together will provide around 700 beds.
The hospital concentrates on solid tumors, brings in established expert teams from China and abroad, and is built around clinical research and public-benefit services rather than around routine care alone. That orientation is what makes a monthly research portfolio worth publishing: for patients who have exhausted standard options, an open study can be a route to a treatment that is not yet commercially available anywhere.
This article is a press summary based on the clinical trial project summary published by Shanghai GOBROAD Cancer Hospital in October 2026. Trial availability, eligibility criteria and study status change over time. It is intended for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Please consult a qualified physician for any medical decision.